Background To determine the frequency and predictive impact of ROS1 rearrangements on
treatment outcomes in never-smoking patients with lung adenocarcinoma. Patients and …

Background c‐ros oncogene 1 (ROS1) rearrangement presents one of the newest molecular
targets in non‐small cell lung cancer (NSCLC). ROS1 rearrangement is predominantly …

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and
genetic variability - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Introduction The presence of ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1)
rearrangements in lung cancers confers sensitivity to ROS kinase inhibitors, including …

Introduction The detection of a ROS1 rearrangement in advanced and metastatic lung
adenocarcinoma (LUAD) led to a targeted treatment with tyrosine kinase inhibitors with …

Background ROS1 rearrangement is a novel molecular subgroup of non-small-cell lung
cancer (NSCLC). This study aimed to investigate the efficacy of crizotinib and pemetrexed …

Introduction Chromosomal rearrangements involving the gene ROS1 define a distinct
molecular subset of NSCLCs with sensitivity to ROS1 inhibitors. Recent reports have …

Introduction The efficacy of pemetrexed-based chemotherapy in patients with advanced lung
adenocarcinoma with novel ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1) …

Introduction The prevalence, demographic features, and clinical outcomes of lung
adenocarcinoma patients with novel ROS1 oncogenic rearrangement in East Asian …

Introduction ROS1-rearranged NSCLC is classified as a distinct molecular subset of NSCLC
with a therapeutic target. ROS1 rearrangement is most often identified in never-smokers with …